Plasmapheresis therapy for rare but potentially fatal reaction to rituximab
Hastings D, Patel B, Torloni AS, Mookadam F, Betcher J, Moss A, Heilman R, Mazur M, Hamawi K, Mulligan D, Reddy K, Mekeel K, Chakkera H. Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. Journal Of Clinical Apheresis 2009, 24: 28-31. PMID: 19156754, DOI: 10.1002/jca.20187.Peer-Reviewed Original ResearchConceptsPlasmapheresis therapyFatal reactionsClinical conditionsHigh-dose vasopressorsHospital day 5Human IgG1 monoclonal antibodyNear-fatal reactionsPatient's clinical conditionIgG1 monoclonal antibodyRituximab therapyInfusion reactionsSupportive careRespiratory compromiseMedical managementCD20 antigenSpecific treatmentDisease processDay 5RituximabMonoclonal antibodiesTherapyMedical communitySubsequent treatmentPlasmapheresisNumerous diseasesUse of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, Mulligan DC, Moss AA, Mekeel KL, Reddy KS. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report. Clinical Transplants 2009, 407-14. PMID: 20524306.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAgedAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntibodies, NeoplasmBoronic AcidsBortezomibCreatinineFemaleGraft RejectionHLA AntigensHumansImmunoglobulins, IntravenousImmunosuppressive AgentsIsoantibodiesKidney TransplantationMaleMiddle AgedProtease InhibitorsPyrazinesRituximabTreatment Outcome